subject area of
- A Comparison of Respiratory Syncytial Viral Prophylaxis in Multiple Births versus Singletons in the Canadian Registry of Palivizumab Academic Article
- A Decade of Respiratory Syncytial Virus Epidemiology and Prophylaxis: Translating Evidence into Everyday Clinical Practice Academic Article
- A Survey of Parental Knowledge of Respiratory Syncytial Virus and Other Respiratory Infections in Preterm Infants Academic Article
- A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS) Academic Article
- A meta-analysis of the effect of antibody therapy for the prevention of severe respiratory syncytial virus infection Academic Article
- A new cost-utility analysis assessing risk factor-guided prophylaxis with palivizumab for the prevention of severe respiratory syncytial virus infection in Italian infants born at 29–35 weeks’ gestational age Academic Article
- A review of cost–effectiveness of palivizumab for respiratory syncytial virus Academic Article
- Adherence and outcomes: a systematic review of palivizumab utilization Academic Article
- Adherence to Palivizumab for Respiratory Syncytial Virus Prevention in the Canadian Registry of Palivizumab Academic Article
- Are late preterm infants as susceptible to RSV infection as full term infants? Academic Article
- CARESS: The Canadian Registry of Palivizumab Academic Article
- Changing costs and the impact on RSV prophylaxis Academic Article
- Comment and reply on: The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32–35 weeks: a Canadian-based analysis Academic Article
- Comparing First- and Second-year Palivizumab Prophylaxis in Patients With Hemodynamically Significant Congenital Heart Disease in the CARESS Database (2005–2015) Academic Article
- Comparison of the Cost of Hospitalization for Respiratory Syncytial Virus Disease Versus Palivizumab Prophylaxis in Canadian Inuit Infants Academic Article
- Current strategies in the prevention of respiratory syncytial virus disease Academic Article
- Does prophylaxis with palivizumab reduce hospitalisation rates for respiratory-syncytial-virus-related infection in cystic fibrosis children less than 2 years of age? Academic Article
- Expert consensus on palivizumab use for respiratory syncytial virus in developed countries Academic Article
- Exploring respiratory syncytial virus prophylaxis for children with all grades of bronchopulmonary dysplasia Academic Article
- First versus second year respiratory syncytial virus prophylaxis in chronic lung disease (2005–2015) Academic Article
- High risk for RSV bronchiolitis in late preterms and selected infants affected by rare disorders: a dilemma of specific prevention Academic Article
- Hospitalization for Respiratory Syncytial Virus Illness in Down Syndrome Following Prophylaxis With Palivizumab Academic Article
- Identifying and Ensuring Optimal Care for All Children at Risk of Developing Serious Respiratory Syncytial Virus Disease: A Canadian Nurses’ Perspective Academic Article
- Impact of using the International Risk Scoring Tool on the cost-utility of palivizumab for preventing severe respiratory syncytial virus infection in Canadian moderate-to-late preterm infants Academic Article
- Outcomes of Infants Receiving Palivizumab Prophylaxis for Respiratory Syncytial Virus in Canada and Italy Academic Article
- Palivizumab Adherence and Outcomes in Canadian Aboriginal Children Academic Article
- Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes Academic Article
- Palivizumab prophylaxis for respiratory syncytial virus in infants with cystic fibrosis: is there a need? Academic Article
- Respiratory Syncytial Virus Immunoprophylaxis with Palivizumab: 12-Year Observational Study of Usage and Outcomes in Canada Academic Article
- Respiratory Syncytial Virus Prophylaxis in Down Syndrome: A Prospective Cohort Study Academic Article
- Respiratory Syncytial Virus Prophylaxis in Immunocompromised Children Academic Article
- Respiratory Syncytial Virus Prophylaxis in Infants With Congenital Diaphragmatic Hernia in the Canadian Respiratory Syncytial Virus Evaluation Study of Palivizumab, 2005–2017 Academic Article
- Respiratory Syncytial Virus Prophylaxis in Neurologic and Muscular Disorders in the Canadian Respiratory Syncytial Virus Evaluation Study of Palivizumab Academic Article
- Respiratory Syncytial Virus in Otherwise Healthy Prematurely Born Infants: A Forgotten Majority Academic Article
- Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations Academic Article
- Respiratory illness and respiratory syncytial virus hospitalization in infants with a tracheostomy following prophylaxis with palivizumab Academic Article
- Respiratory syncytial virus (RSV) infection in children with medical complexity Academic Article
- Respiratory syncytial virus nosocomial outbreak in neonatal intensive care: A review of the incidence, management, and outcomes Academic Article
- Respiratory syncytial virus prophylaxis for children with chronic lung disease: have we got the criteria right? Academic Article
- Respiratory syncytial virus prophylaxis in children with cardiac disease: a retrospective single-centre study Academic Article
- Respiratory syncytial virus prophylaxis in cystic fibrosis: the Canadian registry of palivizumab data (2005–2016) Academic Article
- Respiratory syncytial virus prophylaxis in infants with congenital airway anomalies compared to standard indications and complex medical disorders Academic Article
- Respiratory-Related Hospitalizations following Prophylaxis in the Canadian Registry for Palivizumab (2005–2012) Compared to Other International Registries Academic Article
- Risk of respiratory syncytial virus infection in preterm infants: reviewing the need for prevention Academic Article
- Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33–35 completed weeks’ gestational age in Canada Academic Article
- Seasonal Respiratory Syncytial Virus Prophylaxis Based on Predetermined Dates Versus Regional Surveillance Data Academic Article
- Serious Adverse Events in the Canadian Registry of Children Receiving Palivizumab (CARESS) for Respiratory Syncytial Virus Prevention Academic Article
- The Pediatric Investigators Collaborative Network on Infections in Canada Study of Predictors of Hospitalization for Respiratory Syncytial Virus Infection for Infants Born at 33 Through 35 Completed Weeks of Gestation Academic Article
- The Real-Life Effectiveness of Palivizumab for Reducing Hospital Admissions for Respiratory Syncytial Virus in Infants Residing in Nunavut Academic Article
- The cost effectiveness of palivizumab in congenital heart disease: a review of the current evidence Academic Article
- The cost effectiveness of palivizumab in term Inuit infants in the Eastern Canadian Arctic Academic Article
- The cost effectiveness of palivizumab: a systematic review of the evidence Academic Article
- The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32–35 weeks: a Canadian-based analysis Academic Article
- The impact of prophylaxis on paediatric intensive care unit admissions for RSV infection: a retrospective, single-centre study Academic Article